Pfizer Inc. (NYSE:PFE - Get Free Report)'s stock price traded up 0.5% during trading on Monday . The stock traded as high as $25.74 and last traded at $25.72. 8,249,703 shares were traded during trading, a decline of 78% from the average session volume of 38,361,750 shares. The stock had previously closed at $25.58.
Several equities analysts recently commented on the stock. Citigroup assumed coverage on shares of Pfizer in a report on Friday, October 25th. They set a "neutral" rating and a $30.00 price target on the stock. Wolfe Research started coverage on shares of Pfizer in a research note on Friday, November 15th. They issued an "underperform" rating and a $25.00 target price on the stock. Guggenheim dropped their target price on shares of Pfizer from $35.00 to $33.00 and set a "buy" rating on the stock in a research note on Wednesday, December 11th. Cantor Fitzgerald restated an "overweight" rating and issued a $45.00 target price on shares of Pfizer in a research note on Wednesday, October 23rd. Finally, Sanford C. Bernstein started coverage on shares of Pfizer in a research note on Thursday, October 17th. They issued a "market perform" rating and a $32.00 target price on the stock. One analyst has rated the stock with a sell rating, nine have assigned a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average price target of $32.15.
Get Our Latest Research Report on PFE
The stock's fifty day simple moving average is $27.17 and its 200-day simple moving average is $28.27. The firm has a market cap of $143.09 billion, a PE ratio of 34.18, a PEG ratio of 0.63 and a beta of 0.65. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.
Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping analysts' consensus estimates of $0.64 by $0.42. The firm had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business's quarterly revenue was up 31.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.17) earnings per share. On average, sell-side analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.81%. The ex-dividend date is Friday, January 24th. This is a positive change from Pfizer's previous quarterly dividend of $0.42. Pfizer's dividend payout ratio (DPR) is currently 227.03%.
In related news, Director Scott Gottlieb bought 1,000 shares of the company's stock in a transaction dated Wednesday, October 30th. The shares were acquired at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the transaction, the director now directly owns 10,000 shares in the company, valued at $282,400. This trade represents a 11.11 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.06% of the stock is owned by company insiders.
Several institutional investors have recently modified their holdings of PFE. MFA Wealth Advisors LLC acquired a new stake in shares of Pfizer in the second quarter valued at about $29,000. Gladius Capital Management LP lifted its stake in shares of Pfizer by 102.8% in the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company's stock worth $30,000 after buying an additional 38,015 shares in the last quarter. Quarry LP purchased a new position in shares of Pfizer in the second quarter worth about $31,000. Financial Connections Group Inc. purchased a new position in shares of Pfizer in the second quarter worth about $34,000. Finally, Teachers Insurance & Annuity Association of America purchased a new position in shares of Pfizer in the third quarter worth about $35,000. Institutional investors and hedge funds own 68.36% of the company's stock.
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.